63. 特発性血小板減少性紫斑病
[臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132

Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000030603
2020-05-012020-03-08Clinical study on the safety and efficacy of short - course glucocorticoid treatment in patients with refractory glucocorticoid-dependent primary immune thrombocytopeniaClinical study on the safety and efficacy of short - course glucocorticoid treatment in patients with refractory glucocorticoid-dependent primary immune thrombocytopenia Primary Immune ThrombocytopeniaThe short -course glucocorticoid group:treat with glucocorticoid;The eltrombopag group:treat with eltrombopag;The rituximab group:treat with rituximab;Splenectomy group:treat with splenectomy;The azathioprine group:treat with azathioprine;The cyclosporine group:treat with cyclosporine;The Second Affiliated Hospital of Kunming Medical UniversityNULLPending1875BothThe short -course glucocorticoid group:65;The eltrombopag group:65;The rituximab group:65;Splenectomy group:65;The azathioprine group:65;The cyclosporine group:65;Phase 4China
2ChiCTR1900027753
2019-12-012019-11-25Efficacy and safety of cyclosporine and azathioprine in patients with refractory ITPEfficacy and safety of cyclosporine and azathioprine in patients with refractory ITP Primary Immune ThrombocytopeniaGroup 1:Using cyclosporine A for treatment;Group 2:Using azathioprine for treatment;Control group:Treatment with glucocorticoids;the Second Affiliated Hospital of Kunming Medical UniversityNULLPending1875BothGroup 1:30;Group 2:30;Control group:30;N/AChina